Reduced plasma APOA1 level is associated with Gastric Tumor Growth in MKN45 mouse xenograft model

Journal of Proteomics

Volumn 73, Issue 8, 2010, Pages 1632-1640

  Chong, Poh Kuan ^a   Lee, Huiyin ^a   Zhou, Jianbiao ^a   Liu, Shaw Cheng ^a   Loh, Marie Chiew Shia ^a   So, Jimmy Bok Yan ^b   Lim, Khong Hee ^c   Yeoh, Khay Guan ^d   Lim, Yoon Pin ^a,e,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d Dept Medicine Endocrinol Diabet   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f BIOINFORMATICS INSTITUTE   (Singapore)

Author keywords

APOA1; Cancer marker; Gastric cancer; Plasma; Proteomics

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; COMPLEMENT COMPONENT C3; TUMOR MARKER;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE TAGGING FOR RELATIVE AND ABSOLUTE QUANTIFICATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEIN A-I; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PROTEOMICS; SEQUENCE ALIGNMENT; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 77953124091     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.04.005     Document Type: Article

References (38)

1. Fuchs C.S., and Mayer R.J. Gastric carcinoma. N Engl J Med 333 (1995) 32-41
2. Anderson N.L., and Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1 (2002) 845-867
3. Frese K.K., and Tuveson D.A. Maximizing mouse cancer models. Nat Rev Cancer 7 (2007) 645-658
4. Pitteri S.J., Faca V.M., Kelly-Spratt K.S., Kasarda A.E., et al. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res 7 (2008) 1481-1489
5. van den Bemd G.J., Krijgsveld J., Luider T.M., van Rijswijk A.L., et al. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol Cell Proteomics 5 (2006) 1830-1839
6. Faca V.M., Song K.S., Wang H., Zhang Q., et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5 (2008) e123
7. Bijian K., Mlynarek A.M., Balys R.L., Jie S., et al. Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. J Proteome Res 8 (2009) 2173-2185
8. Juan H.F., Chen J.H., Hsu W.T., Huang S.C., et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 4 (2004) 2766-2775
9. van Weerden W.M., and Romijn J.C. Use of nude mouse xenograft models in prostate cancer research. Prostate 43 (2000) 263-271
10. Orazine C.I., Hincapie M., Hancock W.S., Hattersley M., and Hanke J.H. A proteomic analysis of the plasma glycoproteins of a MCF-7 mouse xenograft: a model system for the detection of tumor markers. J Proteome Res 7 (2008) 1542-1554
11. Wu C.C., Peng P.H., Chang Y.T., Huang Y.S., et al. Identification of potential serum markers for nasopharyngeal carcinoma from a xenografted mouse model using Cy-dye labeling combined with three-dimensional fractionation. Proteomics 8 (2008) 3605-3620
12. Sawaoka H., Kawano S., Tsuji S., Tsujii M., et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274 (1998) G1061-G1067
13. Euhus D.M., Hudd C., LaRegina M.C., and Johnson F.E. Tumor measurement in the nude mouse. J Surg Oncol 31 (1986) 229-234
14. Shilov I.V., Seymour S.L., Patel A.A., Loboda A., et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 6 (2007) 1638-1655
15. Lim Y.P., Low B.C., Lim J., Wong E.S., and Guy G.R. Association of atypical protein kinase C isotypes with the docker protein FRS2 in fibroblast growth factor signaling. J Biol Chem 274 (1999) 19025-19034
16. Lim Y.P., Diong L.S., Qi R., Druker B.J., and Epstein R.J. Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells. Mol Cancer Ther 2 (2003) 1369-1377
17. Pierce A., Unwin R.D., Evans C.A., Griffiths S., et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics 7 (2008) 853-863
18. Gan C.S., Chong P.K., Pham T.K., and Wright P.C. Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J Proteome Res 6 (2007) 821-827
19. Chen Y., Choong L.Y., Lin Q., Philp R., et al. Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol Cell Proteomics 6 (2007) 2072-2087
20. Lam K.W., and Lo S.C. Discovery of diagnostic serum biomarkers of gastric cancer using proteomics. Proteomics Clin Appl 2 (2008) 219-228
21. Wang X., Dai S., Zhang Z., Liu L., et al. Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. Eur J Cancer Care 18 (2009) 625-635
22. Ai J., Tan Y., Ying W., Hong Y., et al. Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics 6 (2006) 538-546
23. Bathen T.F., Krane J., Engan T., Bjerve K.S., and Axelson D. Quantification of plasma lipids and apolipoproteins by use of proton NMR spectroscopy, multivariate and neural network analysis. NMR Biomed 13 (2000) 271-288
24. McVicar J.P., Kunitake S.T., Hamilton R.L., and Kane J.P. Characteristics of human lipoproteins isolated by selected-affinity immunosorption of apolipoprotein A-I. Proc Natl Acad Sci USA 81 (1984) 1356-1360
25. Cheung M.C., and Albers J.J. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 259 (1984) 12201-12209
26. Moore L.E., Fung E.T., McGuire M., Rabkin C.C., et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 15 (2006) 1641-1646
27. Huang H.L., Stasyk T., Morandell S., Dieplinger H., et al. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 27 (2006) 1641-1650
28. Scribano D., Baroni S., Pagano L., Zuppi C., et al. Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. Haematologica 81 (1996) 343-345
29. Yan L., Tonack S., Smith R., Dodd S., et al. Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res 8 (2009) 142-148
30. Kroemer G., and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13 (2008) 472-482
31. Kozak K.R., Su F., Whitelegge J.P., Faull K., et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5 (2005) 4589-4596
32. Zhang Z., Bast Jr. R.C., Yu Y., Li J., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64 (2004) 5882-5890
33. Muntoni S., Atzori L., Mereu R., Satta G., et al. Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis 19 (2009) 218-225
34. Soutar A.K., Hawkins P.N., Vigushin D.M., Tennent G.A., et al. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci USA 89 (1992) 7389-7393
35. Yamamoto T., Suda M., Moriwaki Y., Takahashi S., and Higashino K. Novel apoprotein A-I-containing lipoprotein produced by a human hepatoma-derived cell line HuH-7. Biochim Biophys Acta 1047 (1990) 49-56
36. Forte T.M., McCall M.R., Knowles B.B., and Shore V.G. Isolation and characterization of lipoproteins produced by human hepatoma-derived cell lines other than HepG2. J Lipid Res 30 (1989) 817-829
37. Chisholm J.W., Burleson E.R., Shelness G.S., and Parks J.S. ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J Lipid Res 43 (2002) 36-44
38. Amonkar S.D., Bertenshaw G.P., Chen T.H., Bergstrom K.J., et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PloS one 4 (2009) e4599